Edition:
United States

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

31.35USD
26 Apr 2018
Change (% chg)

$0.70 (+2.28%)
Prev Close
$30.65
Open
$30.70
Day's High
$31.45
Day's Low
$30.25
Volume
29,138
Avg. Vol
282,606
52-wk High
$32.60
52-wk Low
$12.70

Chart for

About

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery... (more)

Overall

Beta: 1.86
Market Cap(Mil.): $2,135.93
Shares Outstanding(Mil.): 70.61
Dividend: --
Yield (%): --

Financials

  HRTX.OQ Industry Sector
P/E (TTM): -- 173.69 32.21
EPS (TTM): -3.65 -- --
ROI: -247.03 -0.70 13.05
ROE: -359.44 -2.69 14.90

BRIEF-Heron Therapeutics Announces Pricing Of Underwritten Public Offering

* HERON THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

Mar 28 2018

BRIEF-Heron Therapeutics Announces Proposed Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 28 2018

BRIEF-Heron Announces Positive Topline Results From Pivotal Phase 3 Clinical Trials Of HTX-011 In Bunionectomy And Hernia Repair

* HERON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIALS OF HTX-011 IN BUNIONECTOMY AND HERNIA REPAIR

Mar 19 2018

BRIEF-Heron Therapeutics Qtrly Net Loss Per Share $1.09

* HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

Feb 27 2018

BRIEF-Heron Therapeutics Announces Pricing Of Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Dec 05 2017

BRIEF-Heron Therapeutics Announces Public Offering Of Common Stock

* HERON THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

Dec 04 2017

BUZZ-Heron Therapeutics: FDA approves chemotherapy-induced nausea drug

** Drug developer's shares rise 4.9 pct to $18.20 after market

Nov 09 2017

BRIEF-Heron Therapeutics gets FDA approval for Cinvanti

* Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv)

Nov 09 2017

BRIEF-Heron Therapeutics reports qtrly diluted net loss per share $0.77

* Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress

Nov 06 2017

Competitors

Earnings vs. Estimates